CTRI/2025/08/092950已完成不适用
An Open Label Balanced Randomized Single Dose Two Treatment Two Sequence Two Period Two Way Crossover Truncated Oral Bioequivalence Study Comparing Cabozantinib 60 mg Tablets Manufactured by BDR Pharmaceuticals International Pvt Ltd India with Cabometyx 60 mg Tablets Imported by Beaufour Ipsen pharmaceuticals Ltd Praca Professor Jose Lannes 40 CJ 101 Sao Paulo SP In Healthy Adult Human Subjects Under Fasting Conditions
BDR pharmaceuticals International Pvt Ltd1 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2025年8月25日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- To assess the Bioequivalence of Cabozantinib 60 mg Tablets Manufactured by BDR Pharmaceuticals International Pvt Ltd India with Cabometyx 60 mg Tablets Imported by Beaufour Ipsen pharmaceuticals Ltd Praca Professor Jose Lannes 40 CJ 101 Sao Paulo SP In Healthy Adult Human Subjects Under Fasting Conditions
研究概览
简要总结
At least 18 number of healthy adult human subjects will be recruited to evaluate the bioequivalence of Test product with the Reference product
As per the discretion of the Investigator a sufficient number of stand-by subjects will be included additionally to ensure successful dosing of 18 subjects in period I alone
In each period, subjects will be housed in the clinical facility for at least 11.00 hours pre dose to 72.00 hours post dose
A washout period of at least 35 days will be maintained between each dosing period
In each period after an overnight fasting of at least 08.00 hours in the morning a single oral dose of either the test product or reference product will be administered as per the randomization schedule with 200 mL of drinking water at ambient temperature
Blood pressure radial pulse rate body temperature and wellbeing status will be enquired and recorded at pre-dose 00.00 hour within 75 minutes of before dosing and at 01.00 02.00 04.00 08.00 12.00 24.00 and 48.00 hours plus or minus 60 minutes post dose
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 盲法
- None
入排标准
- 年龄范围
- 18.00 Year(s) 至 50.00 Year(s)（—）
- 性别
- All
入选标准
- •Normal healthy adult human male and female subjects of age between 18 to 45 years and BodyMass Index BMI ranges between 18.50 kg per m2 to 29.99 kg per m2 Subjects who have no evidence of underlying disease during screening and check in and whosescreening is performed within 21 days of check in Subjects whose screening laboratory values are within normal limits are considered by the physicianor principal or clinical investigator to be of no clinical significance Healthy as documented by the medical history physical examination including but not limited to anevaluation of the cardiovascular gastrointestinal respiratory musculoskeletal and central nervoussystem and vital sign assessments Generally healthy as documented by a 12 lead electrocardiogram ECG Chest X Ray and clinicallaboratory assessments Willing to consume Ovo lacto-vegetarian diet Willing to comply with all requirements of this study protocol as well as instructions from the studypersonnel Non smokers Generally healthy, as documented by gynaecological examination and breast examination period Ionly Females of childbearing potential must have a negative serum pregnancy test performed within 21days prior to the initiation of the study and a negative urine pregnancy test prior to check in foreach period If the subject is female currently not pregnant not lactating or not attempting to become pregnantfor 4 weeks before the screening visit throughout the duration of the study and 3 weeks after thesubjects last study related visit for eligible subjects only if applicable has a negative serumpregnancy test and is of non-childbearing potential defined as greater or equal to 01 year post menopausal no menstrual period for at least 12 consecutivemonths without any other medical cause Surgically sterile bilateral tubal ligation bilateral oophorectomy or hysterectomy or is of childbearing potential willing to commit to using a consistent and acceptable method of birth controlas defined below for the duration of the study double barrier methods condoms cervical cap diaphragm and vaginal contraceptive film withspermicide intrauterine device IUD with a low failure rate of less than 1 percentage per year or is of childbearing potential and not sexually active willing to commit to using a consistent and acceptablemethod of birth control as defined above for the duration of the study in the event the subjectbecomes sexually active.
排除标准
- •Evidence of allergy or known hypersensitivity to Cabozantinib or its inactive ingredients Subjects with hepatic encephalopathy cholestasis myasthenia pre existing liver disease alcohol abuse existing tinnitus and pre existing gallbladder disease Any major illness in the last three months or any significant ongoing chronic medical illness Renal or liver impairment Any disease or condition that might compromise the haemopoeitic gastrointestinal renal hepatic cardiovascular Musculoskeletal respiratory central nervous system or any other body system including presence of Diabetes Mellitus and Psychosis History of alcohol addiction or abuse Consumption of caffeine and or xanthine containing products i.e. coffee tea chocolate caffeine containing sodas colas etc cigarettes and tobacco containing products for at least 48:00 hours prior to check-in and throughout the entire study Consumption of alcohol and its products grapefruit and or its juice, and poppy containing foods within 48:00 hours prior to clinic admission and throughout the entire study Subjects who have taken any prescription medications within 14 days prior to study check in and throughout the study and any over the counter medicinal products herbal medications within 07 days prior to study check-in and throughout the study Subjects who have taken any unusual diet for whatever reason eg low salt for 48.00 hours prior to dosing and throughout the study Subject who had participated in any other study within the 90 days of check in History of difficulty in accessibility of veins Positive results for urine screen of drugs of abuse Marijuana THC amphetamine-AMP barbiturates BAR cocaine COC benzodiazepines BZD and morphine MOR in urine prior to check-in of each period Positive results for alcohol test prior to check-in of each period Any blood donation or excess blood loss within 90 days of check in Ingestion of any hormonal agent at any time within 14 days prior to the start of the study check in Use of hormone replacement therapy for a period of 06 months prior to dosing Female subjects demonstrating a positive pregnancy screen Female subjects who are currently lactating Females are likely to become pregnant during the course of the study.
结局指标
主要结局
To assess the Bioequivalence of Cabozantinib 60 mg Tablets Manufactured by BDR Pharmaceuticals International Pvt Ltd India with Cabometyx 60 mg Tablets Imported by Beaufour Ipsen pharmaceuticals Ltd Praca Professor Jose Lannes 40 CJ 101 Sao Paulo SP In Healthy Adult Human Subjects Under Fasting Conditions
时间窗: 24 Time points | 00 00 hrs 00 50 hrs 01 00 hrs 01 50 hrs 02 00 hrs 02 33 hrs 02 67 hrs 03 00 hrs 03 25 hrs 03 50 hrs 03 75 hrs 04 00 hrs 04 33 hrs 04 67 hrs 05 00 hrs 05 50 hrs 06 00 hrs 07 00 hrs 08 00 hrs 10 00 hrs 12 00 hrs 24 00 hrs 48 00 hrs 72 00 hrs
次要结局
- To monitor the safety and tolerability of test product comparing with the reference product in healthy adult human subjects under fasting conditions(24 Time points 00 00 hrs 00 50 hrs 01 00 hrs 01 50 hrs 02 00 hrs 02 33 hrs 02 67 hrs 03 00 hrs 03 25 hrs 03 50 hrs 03 75 hrs 04 00 hrs 04 33 hrs 04 67 hrs 05 00 hrs 05 50 hrs 06 00 hrs 07 00 hrs 08 00 hrs 10 00 hrs 12 00 hrs 24 00 hrs 48 00 hrs 72 00 hrs)
研究者
Dr Pradeep T
Spinos Lifescience and research private limited
研究点 (1)
Loading locations...
相似试验
已完成
不适用
An Open Label Single Dose Two Treatment Three Period Partial Replicate Reference scaled Oral Bioequivalence Study Comparing Valsartan and Hydrochlorothiazide Tablets In Healthy Adult Human Subjects Under Fasting ConditionsCTRI/2025/02/081390Incepta Pharmaceuticals Ltd60
尚未招募
不适用
A Single Dose Four Period Study Comparing Diclofenac Tablet 100 mg In Healthy Adult Human Subjects Under Fasting ConditionsCTRI/2025/08/093013Unique Pharmaceutical Laboratories36
尚未招募
不适用
A Single Dose Four Period Study Comparing Diclofenac Sodium Tablet 100 mg In Healthy Adult Human Subjects Under Fed ConditionsCTRI/2025/08/093119Unique Pharmaceutical Laboratories36
已完成
不适用
An Open Label Single Dose Crossover Oral Bioequivalence Study Comparing Elobixibat 5 mg In Healthy Adult Human Subjects Under Fasting ConditionCTRI/2025/03/081536BDR Pharmaceuticals Private limited32
已完成
不适用
An Open Label Single Dose Two Period Oral Bioequivalence Design In Healthy Adult Human Subjects Under Fasting ConditionsCTRI/2025/10/095859BDR pharmaceuticals International Pvt Ltd42